We caught up with Meletios-Athanasios Dimopoulos (National and Kapodistrian University of Athens School of Medicine, Athens, Greece) to discuss his ASH 2020 presentation on the use of daratumumab in the treatment of relapsed/refractory multiple myeloma (Clinical Trial Identification: NCT03180736). The abstract ‘412 Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)‘ (ABSTRACT NUMBER: 412) was presented at the Virtual 2020 ASH Congress, 2–10 December 2020.
Questions
- What are the major challenges and unmet needs when treating relapsed/refractory multiple myeloma? (0:08)
- What is the mode of action of daratumumab, and pomalidomide and dexamethasone, and what is the rationale behind the Apollo trial? (0:42)
- What were the aims and design of the Apollo trial? (3:00)
- What were the major safety and efficacy findings presented at this year’s ASH congress? (4:20)
- What will be the next steps in the clinical development of daratumumab, and how may it fit into treatment strategies? (6:08)
Speaker Disclosures: Meletios-Athanasios Dimopoulos discloses honoraria from participation in advisory boards from Amgen, Takeda, Beigene, Janssen and BMS.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.
